THRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theseus Pharmaceuticals's Enterprise Value is $-20.19 Mil. Theseus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-66.52 Mil. Therefore, Theseus Pharmaceuticals's EV-to-EBIT ratio for today is 0.30.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Theseus Pharmaceuticals's Enterprise Value is $-20.19 Mil. Theseus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-66.44 Mil. Therefore, Theseus Pharmaceuticals's EV-to-EBITDA ratio for today is 0.30.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Theseus Pharmaceuticals's Enterprise Value is $-20.19 Mil. Theseus Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Theseus Pharmaceuticals's EV-to-Revenue ratio for today is .
The historical data trend for Theseus Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theseus Pharmaceuticals Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Enterprise Value | - | - | 246.09 | -1.10 |
Theseus Pharmaceuticals Quarterly Data | |||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Enterprise Value | Get a 7-Day Free Trial | 16.22 | -1.10 | 154.20 | 202.38 | -84.17 |
For the Biotechnology subindustry, Theseus Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Theseus Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Theseus Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
Enterprise Value (A: Dec. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 192.89781 | + | 0 | + | 3.236 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.743 | + | 0 | - | 197.979 |
= | -1.10 |
Theseus Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 is calculated as
Enterprise Value (Q: Sep. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 117.297719 | + | 0 | + | 2.897 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.759 | + | 0 | - | 205.122 |
= | -84.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theseus Pharmaceuticals (NAS:THRX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Theseus Pharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -20.190 | / | -66.524 | |
= | 0.30 |
Theseus Pharmaceuticals's current Enterprise Value is $-20.19 Mil.
Theseus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.52 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Theseus Pharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | -20.190 | / | -66.441 | |
= | 0.30 |
Theseus Pharmaceuticals's current Enterprise Value is $-20.19 Mil.
Theseus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.44 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Theseus Pharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -20.190 | / | 0 | |
= |
Theseus Pharmaceuticals's current Enterprise Value is $-20.19 Mil.
Theseus Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Theseus Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Foresite Capital Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Hayden Donald J Jr | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Bradford D. Dahms | officer: Chief Financial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Timothy P Clackson | director, officer: President and CEO | C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Steven H Stein | director | 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803 |
Foresite Capital Opportunity Management V, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Opportunity Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Management V, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
James B. Tananbaum | 10 percent owner | 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115 |
William Shakespeare | officer: See Remarks | 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Rock Springs Capital Master Fund Lp | 10 percent owner | 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001 |
Omega Fund Vi Gp Manager, Ltd. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Orbimed Capital Gp Vii Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 08-03-2022
By PRNewswire PRNewswire • 07-08-2022
By PRNewswire PRNewswire • 05-31-2023
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire • 11-14-2023
By PRNewswire • 11-14-2023
By PRNewswire • 01-23-2024
By PRNewswire PRNewswire • 08-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.